Hippocampal atrophy in epilepsy …

Fernando Cendes MD PhD

Epilepsy & Seizures

Updated 06.24.2024
Released 12.30.2014
Expires For CME 06.24.2027

Hippocampal atrophy in epilepsy

Author: Fernando Cendes MD PhD

See Contributor Disclosures

Editor: Jerome Engel Jr MD PhD

Hippocampal atrophy in epilepsy

In This Article

Quick Link

Introduction

Overview

In this article, the authors present data and discussion about the causes, syndromes, diagnosis, and management of hippocampal atrophy and epilepsy.

Key points

	• Hippocampal atrophy is the most important MRI finding in histologically proven hippocampal sclerosis, particularly when associated with hyperintense signal in T2-weighted MRI sequences.
	• Hippocampal atrophy associated with mesial temporal lobe epilepsy is one of the most frequent forms of epilepsy with focal onset.
	• Some patients have an excellent response to antiseizure medication treatment, whereas most patients are pharmacoresistant.
	• Surgical treatment yields better seizure control than medical treatment in those who failed initial antiseizure medication treatment.
	• There is evidence that hippocampal atrophy progresses over time; however, most of the hippocampal damage is caused by an early insult that may precede seizure onset.

Clinical manifestations

Presentation and course

The typical history of mesial temporal lobe epilepsy with hippocampal sclerosis describes the occurrence of an initial precipitating injury, such as prolonged febrile seizures, CNS infection, and trauma, followed by a latent period until the onset of habitual seizures (67). However, the initial precipitating injury is not frequently identified (25). Particular attention has been directed to the well-known association between prolonged febrile seizures (and febrile status epilepticus) in early infancy and the development of mesial temporal sclerosis (21). However, the exact causal relationship between febrile seizures, temporal lobe epilepsy, and hippocampal sclerosis has not yet been totally elucidated. Advances in clinical and molecular genetic studies strongly suggest a role of genetic factors, implying a causal role of febrile status epilepticus in the development of temporal lobe epilepsy (75).

The first ictal event may be either a focal seizure with impaired awareness or a focal to bilateral tonic-clonic seizure (40). Usually, before the focal impaired awareness seizures, patients present a typical aura characterized by an indeterminate visceral sensation, described as a rising epigastric sensation, nausea, or “butterflies.” It can be associated with fear, autonomic (such as tachycardia, pallor), or other psychic (eg, déjà vu, jamais vu) symptoms. Some patients may also present olfactory and gustatory sensations (25; 75). The occurrence of isolated auras without focal impaired awareness seizures is not uncommon, even years preceding the habitual seizures (57; 56; 06).

The focal impaired awareness seizures characteristically involve impairment of consciousness or awareness and usually initiate with motionless staring that may or may not be accompanied by oroalimentary automatisms (eg, chewing, lip smacking) (07; 06). Concurrent to the impairment of awareness, there may be additional lateralization signs, such as contralateral dystonic posturing or verbal automatisms (when seizures arise from the nondominant hemisphere). A postictal confusional state or aphasia (if the seizure arises from the language-dominant hemisphere) is frequent (25).

Mesial temporal lobe epilepsy with hippocampal sclerosis is highly associated with pharmacoresistant seizures; however, there are patients who respond well to antiseizure medication (57; 60). Patients with mesial temporal lobe epilepsy and hippocampal atrophy who have been seizure-free for at least 24 months with or without medication, and who are not surgical candidates, have been recognized more frequently (02). Some of these patients belong to families with mesial temporal lobe epilepsy (57). Most patients with familial mesial temporal lobe epilepsy have few seizures during their lifetimes or respond well to antiseizure medication. Over time, they persist with the same clinical status (ie, they do not develop pharmacoresistant epilepsy), as observed in a longitudinal study of 17 families with long-term follow-up (72). There are also patients with sporadic mesial temporal lobe epilepsy with late-onset seizures who respond well to antiseizure medication (60).

Patients with mesial temporal lobe epilepsy with hippocampal sclerosis who respond well to antiseizure medication have an older age at epilepsy onset and a less frequent history of early febrile seizures compared to those who are pharmacoresistant (28).

Patients with pharmacoresistant mesial temporal lobe epilepsy associated with hippocampal atrophy have significantly more social, psychiatric, and cognitive dysfunction than those with well-controlled seizures and, consequently, more stigma and difficulties in employment and schooling (58; 74). These difficulties are, in part, associated with recurrent seizures and, in part, related to cognitive dysfunction, which typically affects memory (58). Verbal memory is predominantly affected when the hippocampal atrophy occurs in the hemisphere dominant for language; on the contrary, when the hippocampal atrophy is in the nondominant hemisphere, deficits in visual memory are more severe (01). In addition, these subjects present other behavioral comorbidities such as depression and psychosis, which may contribute to social problems (79; 53; 74). Also, temporal lobe epilepsy patients with left-sided hippocampal atrophy have worse brain dysfunction as compared to those with right-sided hippocampal atrophy and those without atrophy (77; 97).

Especially in pharmacoresistant patients, accidents may occur involving burns, bone and teeth fractures, as well as head trauma due to frequent falls (32). There is also an increased risk of sudden death in these patients (05).

Pathophysiology

Hippocampal atrophy associated with hippocampal sclerosis in epilepsy is a network disorder, functionally and structurally (11; 95; 33; 77; 97). Hippocampal sclerosis is characterized by a selective pattern of neuronal loss within the subfields that distinguish it from other types of hippocampal atrophy not related to epilepsy, such as in Alzheimer disease or normal aging. In addition to the segmental neuronal cell loss, there is usually astrogliosis, mossy fiber sprouting, and granule cell dispersion (25; 68). Over the years, there have been many classifications of hippocampal sclerosis proposed, and in 2013, a neuropathology taskforce was designated by the ILAE to incorporate the previous schemes into a consensus (14). The histopathological characterization includes three types of hippocampal sclerosis with one additional term: “Gliosis only, no hippocampal sclerosis” (14).

Hippocampal sclerosis ILAE type 1. This type is the most frequent pattern identified in the surgical series (classic and total forms of hippocampal sclerosis, 60% to 80% of the cases). There is approximately 80% loss of neurons in the CA1 section, associated with loss of neurons in CA2 (30% to 50%), CA3 (30% to 90%), and CA4 (40% to 90%). There is also loss of granule cell of dentate gyrus (approximately 50% to 60%).

Hippocampal sclerosis ILAE type 2. This type represents a rare pattern of hippocampal sclerosis (5% to 10%). In this pattern, the entire CA1 section is affected, with mild neuronal loss in the other subfields.

Hippocampal sclerosis ILAE type 3. This type is also an infrequent pattern of hippocampal sclerosis, occurring in only 4% to 7% of the surgical cases. There is marked loss in CA4 (approximately 50%) and dentate gyrus (more than 30% of granular neurons), with moderate neuronal loss in the remaining subfields. It has been associated with dual pathologies and limbic encephalitis.

Gliosis only, no hippocampal sclerosis. This type is present in nearly 20% of surgical specimens and shows reactive gliosis without significant neuronal loss.

The diagnosis of dual pathology is applied when hippocampal sclerosis occurs in the presence of other pathologies outside the mesial temporal lobe (neoplasm, vascular lesions, glial scar, limbic/Rasmussen encephalitis, or malformation of cortical development) (15; 25).

The mechanisms underlying the development of hippocampal sclerosis remain undetermined. Hippocampal sclerosis most likely has different causes in different individuals and may result from complex interactions among genetic and environmental factors (25).

Studies have shown that prolonged and focal febrile seizures can produce acute hippocampal injury that evolves into hippocampal atrophy and that complex febrile seizures can originate in the temporal lobes in some children (69). Although there is a high incidence of complex febrile seizures among patients with mesial temporal sclerosis in retrospective studies, it is still not clear whether complex febrile seizures are an epiphenomenon or a causative factor, or both (66).

A longitudinal MRI study in children showed that hippocampal T2 hyperintensity following febrile status epilepticus predicted hippocampal sclerosis and a significant likelihood of mesial temporal lobe epilepsy, whereas normal hippocampal appearance in the acute postictal MRI was followed by normal hippocampi and lower risk of epilepsy (61). However, due to the lack of MRI before the status, that study cannot rule out preexisting hippocampal abnormalities (08; 61).

Genetic predisposition appears to be an important causal factor in patients with hippocampal sclerosis and antecedent prolonged febrile seizures (09; 54). Clinical and molecular genetic studies show that there is some specificity in the types of epilepsy that follow febrile seizures, rather than febrile seizures being a nonspecific marker of a lowered seizure threshold. The relationship between febrile seizures and later development of epilepsy appears to have a strong genetic background (09).

Evidence from experimental and clinical studies also provides data suggesting the importance of innate immunity in the etiology and pathogenesis of mesial temporal lobe epilepsy. The presence of inflammatory processes, indicated, for example, by the presence of highly upregulated chemokines genes in chronic mesial temporal lobe epilepsy (88) may directly and indirectly affect neuronal excitability.

Studies of autoimmune epilepsy and limbic encephalitis have described pharmacoresistant seizures, cognitive deficits, and presence of abnormalities in the mesial temporal region, including hippocampal atrophy (89; 20; 39). Autoimmune limbic encephalitis has been associated with a variety of pathogenic antibodies targeting neuronal antigens, including LGI1 (leucine-rich, glioma inactivated 1), NMDA receptor (N-methyl-D_aspartate), as well as onconeural antibodies such as Hu and Ma2Ta and others (62; 42).

The relationship between autoimmune epilepsy, limbic encephalitis, and hippocampal atrophy remains unclear and requires further longitudinal studies. Whether some subjects with temporal lobe epilepsy and hippocampal atrophy represent “mild forms of limbic encephalitis” is debatable and needs further investigation (42). According to Gaspard, some clinical features should raise the awareness of possible autoimmune basis for epilepsy, including: onset with status epilepticus, early pharmacoresistance, rapid cognitive decline, onset after 30 years, mesial temporal inflammatory findings on brain MRI, and bilateral mesial temporal findings on brain MRI (42). Future studies may clarify the impact of the autoimmune process on development of hippocampal atrophy and perhaps allow new treatment strategies to avoid pharmacoresistant seizures.

Other brain injuries and infections may be related to the underlying causes of hippocampal atrophy. Chronic autoimmune inflammation after viral encephalitis, such as herpes virus, could also be a potential underlying cause of hippocampal atrophy, in addition to the acute damage caused by the viral infection (78). There is a high frequency of hippocampal atrophy in patients with calcified neurocysticercosis and pharmacoresistant seizures, suggesting a possible association between these two conditions (83; 49; 80; 81). Some mesial temporal lobe epilepsies with hippocampal atrophy, usually bilateral, appear to result from traumatic brain injuries (36).

Diagnostic workup

Neuropsychological tests. Neuropsychological evaluation commonly demonstrates memory dysfunction, which is material-specific according to the hemisphere involved and is related to the degree of hippocampal atrophy on MRI and cell loss on postoperative histopathology. Verbal memory is mostly affected with left-sided hippocampal atrophy, whereas visuospatial memory is more affected with right-sided hippocampal atrophy (52).

EEG. Interictal EEG findings in patients with mesial temporal lobe epilepsy and hippocampal atrophy typically include unilateral or bilaterally independent mesial temporal spikes, best seen with basal (sphenoidal, inferior temporal) derivations. In patients with MRI-defined unilateral hippocampal sclerosis, the interictal epileptiform discharges are predominantly or exclusively ipsilateral to the hippocampal atrophy, even after decades of ongoing seizures (18). Contralateral interictal epileptiform discharges appear to reflect early widespread abnormalities and not epilepsy progression. Temporal intermittent rhythmic delta activity appears to have a localizing value of the epileptogenic zone in mesial temporal lobe epilepsy, unlike intermittent rhythmic delta activity in other brain regions (41).

Ictal EEG recordings usually reveal ictal onset consisting of regular, well-lateralized, rhythmic 5- to 9-Hz activity in one anterior-mid and inferomesial temporal region before the first clinical manifestations or within 30 seconds (delayed focal onset), with or without contralateral propagation. However, artifacts due to oromasticatory movements and other automatisms early in the clinical manifestations frequently obscure the ictal scalp EEG recordings (24).

Ictal discharges may be confined to the medial temporal structures for a few seconds or longer, without evident EEG changes on scalp recordings. This may be followed by a fast propagation of seizure discharges to the ipsilateral or contralateral temporal neocortex, or it may propagate to both hemispheres in a diffuse fashion. In these circumstances, the scalp EEG record may miss the initial (truly localizing) seizure discharges. Thus, ictal scalp EEG recordings may have limited localizing value when the first clinical manifestations clearly precede the first EEG changes. This false localization phenomenon may be associated with severe hippocampal damage (70).

Although diagnosis of mesial temporal lobe epilepsy with hippocampal sclerosis and identification of the side of ictal onset for surgical therapy is now possible in most patients using noninvasive investigation (03), additional long-term monitoring with intracranial electrodes may be indicated when the side of mesial temporal ictal onset is unclear or there remains a possibility of neocortical ictal onset (50; 37). Most centers utilize depth electrodes for this purpose, but subdural strips or grids and foramen ovale electrodes can also be used (24).

Neuroimaging. When there is a clinical suspicion of mesial temporal lobe epilepsy, MRI can provide a noninvasive and highly accurate diagnostic method to detect hippocampal atrophy and other signs of hippocampal sclerosis in vivo (25). The optimization of acquisition protocol is necessary for adequate evaluation of hippocampal morphology, including thin high-resolution T2-weighted coronal slices (3 mm maximum) obtained on a plane perpendicular to the long axis of the hippocampus; high-resolution 1 mm volumetric (3D) T1-weighted images; and coronal, or preferentially, 3D-FLAIR (fluid attenuation inversion recovery) images (10). The visual inspection of MRI may provide clear information when the asymmetry of hippocampi is evident, facilitating the identification of hippocampal atrophy. Typically, atrophy of the hippocampus is associated with increased T2-weighted signal (25).

Left mesial temporal lobe epilepsy (MRI)

Coronal T1 inversion recovery and T2 FLAIR (left) and axial FLAIR MRI showing left hippocampal atrophy and hyperintense FLAIR signal (arrows) in a patient with left mesial temporal lobe epilepsy. (Contributed by Clarissa Lin Yasud...

Studies with proton magnetic resonance spectroscopy (¹H-MRS) show associated reduction of neuronal marker N-acetylaspartate in mesial temporal lobe epilepsy (even in subjects without clear hippocampal sclerosis) (22; 77). The quantification of T2 relaxometry may provide additional information about the lateralization as hyperintense T2 signal in the hippocampus is associated with hippocampal sclerosis and concordant with EEGs (30; 31).

However, the visual analysis may not offer straightforward results when there is bilateral atrophy or mild unilateral hippocampal atrophy. As the identification of atrophic hippocampus may be crucial for surgical planning, additional tools can be used to detect more subtle abnormalities that can define the lateralization of atrophy. Volumetry of the hippocampus can provide very accurate information about lateralization of the temporal lobe epilepsy, which can be used for surgical treatment (22). Automatic models to obtain hippocampal volume have been developed and compared in order to facilitate the identification of morphometric abnormalities (73; 65). Automated imaging assessment tools can assist clinical radiology reporting of hippocampal sclerosis, improving detection accuracy in clinical practice (44; 59). Machine learning algorithms using multimodal MRI have been promising in lateralizing hippocampal pathology in patients with temporal lobe epilepsy and hippocampal sclerosis and may have clinical applications in the near future (19; 43).

Other functional tests such as [18F] fluorodeoxyglucose (FDG)-PET and ictal SPECT may help to lateralize the seizure origin, especially when EEGs show bilateral epileptiform activity (46; 93; 25). The temporal lobe with hippocampal atrophy is usually hypometabolic on interictal FDG-PET, with an area that involves the mesial structures and other parts of the temporal lobe, which is helpful and reliable in localization for surgical treatment (25; 26). Although ictal and early postictal SPECT scans can be helpful in localizing the epileptogenic focus in patients with mesial temporal lobe epilepsy, it is logistically difficult and is not routinely performed in most centers (90).

Management

Clinical treatment. The initial treatment should aim at maximum tolerated doses of antiseizure medications, taking into account that some patients may respond well to treatment despite the presence of hippocampal atrophy. However, it is important to recognize pharmacoresistant patients without delay (87). These patients should be referred to comprehensive epilepsy centers for evaluation of possible surgical treatment to prevent further cognitive dysfunction as well as death (51). There is Class I evidence for better efficacy of surgery compared to continuing with further antiseizure medication trials in patients with mesial temporal lobe epilepsy with hippocampal sclerosis who failed treatment with two or more AEDs (91; 38).

The initial treatment should be a single antiseizure medication at a low dose gradually incremented over weeks to establish an effective and tolerable regimen. Further dose adjustments can be made according to the clinical response (45). The choice of antiseizure medication needs to be assessed individually and consider several factors, including the adverse effect profile of each medication and the potential teratogenic effect on women, age, and comorbidities.

Second- and third-generation antiseizure medications are less likely to cause pharmacokinetic interactions than older antiseizure medications (76). Some second-generation antiseizure medications have advantages in tolerability and safety, particularly in treating older patients and women of childbearing potential (eg, lamotrigine). Unfortunately, none of the newer antiseizure medications have more efficacy than the older antiseizure medications (76).

A study comparing the effectiveness of antiseizure medications in patients with mesial temporal lobe epilepsy with hippocampal sclerosis showed that seizure improvement was highest for the first antiseizure medications prescribed and lowest for subsequent antiseizure medications (04). Seizure‐freedom rates were highest with carbamazepine, levetiracetam, and oxcarbazepine. The highest 12‐month retention rates were with carbamazepine (85.9%), valproate (85%), and clobazam (79%) (04). The highest adverse reaction rates were with oxcarbazepine (35.7%), topiramate (30.9%), and pregabalin (27.4%), and the lowest rates were with clobazam (6.5%), gabapentin (8.9%), and lamotrigine (16.6%).

Unfortunately, a significant proportion of patients with mesial temporal lobe epilepsy with hippocampal sclerosis will eventually present with refractory seizures and require polytherapy. In general, polytherapy increases the risk of undesired side effects and teratogenicity (47; 92; 17; 04; 76). The ideal combination should provide “supra-additive efficacy with infra-additive toxicity” (17). However, this is not always achieved and usually yields some degree of undesired side effects. Robust evidence to guide when and how to combine antiseizure medications is still lacking (84; 76). Therefore, the decision should consider both comedication and comorbidities to optimize the best options individually. Some examples of synergism are the combination of lamotrigine and valproate, carbamazepine with clobazam, and lacosamide with levetiracetam (71; 29; 96).

Despite the absence of evidence-based guidelines to recommend appropriate immunotherapy in patients with limbic encephalitis and hippocampal atrophy, current alternatives (based mostly on observational evidence) include intravenous steroids, intravenous immunoglobulin, plasma exchange, rituximab, and cyclophosphamide (42). The combination of immunotherapy and antiseizure medications provides relatively good control of seizures (89), although some subjects develop hippocampal atrophy and persist with pharmacoresistant seizures, requiring surgical treatment (20).

Surgical treatment. The removal of mesial temporal lobe structures has been indicated for pharmacoresistant patients (91). Different surgical approaches have been proposed, including more selective amygdalohippocampectomy and standard temporal lobectomy (48; 35). There are two class I studies confirming the superiority of surgical treatment over prolonged medical treatment for patients who had inadequate responses to antiseizure medications (91; 38). In one of the studies, 23 patients continued antiseizure medications and 15 underwent anteromesial temporal resection with antiseizure medication treatment. After two years of follow-up, 73% of operated patients were seizure-free, compared to none of the medical group (38).

In a study of 213 patients with a neuropathological diagnosis of hippocampal sclerosis and a minimum follow-up of two years, the authors divided the subjects according to ILAE hippocampal sclerosis type 1 or 2 and further classified them into three groups: isolated hippocampal sclerosis, hippocampal sclerosis associated with focal cortical dysplasia, or hippocampal sclerosis associated with other lesions (34). Regardless of the hippocampal sclerosis type and associated pathology, they observed greater than 80% of Engel class I for both short- and long-term outcomes. Patients with hippocampal sclerosis type 2 (cell loss predominantly in CA1) presented a better long-term outcome than those with hippocampal sclerosis type 1 (cell loss in all sectors of CA). The presence of focal cortical dysplasia was associated with a worse outcome (regardless of hippocampal sclerosis type), whereas a shorter duration of epilepsy correlated with seizure freedom after surgery (34).

Given the evidence, efforts should be directed to reduce the time to surgical referral, offering patients higher chances of earlier seizure control and improvement in quality of life and avoidance of disability (38).

References

01: Alessio A, Kobayashi E, Damasceno BP, Lopes-Cendes I, Cendes F. Evidence of memory impairment in asymptomatic individuals with hippocampal atrophy. Epilepsy Behav 2004;5(6):981-7. PMID 15582848
02: Alvim MKM, Coan AC, Campos BM, et al. Progression of gray matter atrophy in seizure-free patients with temporal lobe epilepsy. Epilepsia 2016;57(4):621-9. PMID 26865066
03: Alvim MKM, Morita ME, Yasuda CL, et al. Is inpatient ictal video-electroencephalographic monitoring mandatory in mesial temporal lobe epilepsy with unilateral hippocampal sclerosis? A prospective study. Epilepsia 2018;59(2):410-9. PMID 29238960
04: Androsova G, Krause R, Borghei M, et al. Comparative effectiveness of antiepileptic drugs in patients with mesial temporal lobe epilepsy with hippocampal sclerosis. Epilepsia 2017;58(10):1734-41. PMID 28857179
05: Bardai A, Lamberts RJ, Blom MT, et al. Epilepsy is a risk factor for sudden cardiac arrest in the general population. PloS One 2012;7(8):e42749. PMID 22916156
06: Baulac M. MTLE with hippocampal sclerosis in adult as a syndrome. Rev Neurol (Paris) 2015;171(3):259-66. PMID 25727907
07: Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 2010;51(4):676-85. PMID 20196795
08: Berg MJ, Abou-Khalil B. Childhood febrile status epilepticus: chicken or egg? Does it matter? Neurology 2012;79(9):840-1. PMID 22843273
09: Berkovic SF, Scheffer IE. Febrile seizures: genetics and relationship to other epilepsy syndromes. Curr Opin Neurol 1998;11(2):129-34. PMID 9551293
10: Bernasconi A, Cendes F, Theodore WH, et al. Recommendations for the use of structural magnetic resonance imaging in the care of patients with epilepsy: a consensus report from the International League Against Epilepsy Neuroimaging Task Force. Epilepsia 2019;60(6):1054-68. PMID 31135062
11: Bernhardt BC, Bonilha L, Gross DW. Network analysis for a network disorder: The emerging role of graph theory in the study of epilepsy. Epilepsy Behav 2015;50:162-70. PMID 26159729
12: Blumcke I, Aronica E, Urbach H, Alexopoulos A, Gonzalez-Martinez JA. A neuropathology-based approach to epilepsy surgery in brain tumors and proposal for a new terminology use for long-term epilepsy-associated brain tumors. Acta Neuropathol 2014;128(1):39-54. PMID 24858213
13: Blumcke I, Coras R, Miyata H, Ozkara C. Defining clinico-neuropathological subtypes of mesial temporal lobe epilepsy with hippocampal sclerosis. Brain Pathol 2012;22(3):402-11. PMID 22497612
14: Blumcke I, Thom M, Aronica E, et al. International consensus classification of hippocampal sclerosis in temporal lobe epilepsy: a Task Force report from the ILAE Commission on Diagnostic Methods. Epilepsia 2013;54(7):1315-29. PMID 23692496
15: Blumcke I, Thom M, Aronica E, et al. The clinicopathologic spectrum of focal cortical dysplasias: a consensus classification proposed by an ad hoc Task Force of the ILAE Diagnostic Methods Commission. Epilepsia 2011;52(1):158-74. PMID 21219302
16: Bouchet C, Cazauvieilh CA. De l' épilepsie considerée dans ses rapports avec l'aliénation mentale. Recherche sur la nature et le siège de ces deux maladies. Arch Gen Med 1825;9:510-42.
17: Brigo F, Ausserer H, Tezzon F, Nardone R. When one plus one makes three: the quest for rational antiepileptic polytherapy with supraadditive anticonvulsant efficacy. Epilepsy Behav 2013;27(3):439-42. PMID 23591263
18: Brito MR, Prado TS, Alvim MKM, et al. Longitudinal analysis of interictal electroencephalograms in patients with temporal lobe epilepsy with hippocampal sclerosis. Seizure 2021;90:141-4. PMID 33608133
19: Caldairou B, Foit NA, Mutti C, et al. MRI-based machine learning prediction framework to lateralize hippocampal sclerosis in patients with temporal lobe epilepsy. Neurology 2021;97(16):e1583-93. PMID 34475125
20: Carreno M, Bien CG, Asadi-Pooya AA, et al. Epilepsy surgery in drug resistant temporal lobe epilepsy associated with neuronal antibodies. Epilepsy Res 2017;129:101-5. PMID 28043058
21: Cendes F. Febrile seizures and mesial temporal sclerosis. Curr Opin Neurol 2004;17(2):161-4. PMID 15021243
22: Cendes F, Caramanos Z, Andermann F, Dubeau F, Arnold DL. Proton magnetic resonance spectroscopic imaging and magnetic resonance imaging volumetry in the lateralization of temporal lobe epilepsy: a series of 100 patients. Ann Neurol 1997;42(5):737-46. PMID 9392573
23: Cendes F, Cook MJ, Watson C, et al. Frequency and characteristics of dual pathology in patients with lesional epilepsy. Neurology 1995;45(11):2058-64. PMID 7501159
24: Cendes F, Kahane P, Brodie MJ, Andermann F. The mesio-temporal lobe epilepsy syndrome. In: Bureau M, Genton P, Dravet C, et al, editors. Epileptic syndromes in infancy, childhood and adolescence. 5th edition. Eastleigh, UK: John Libbey Eurotext Ltd, 2012.
25: Cendes F, Sakamoto AC, Spreafico R, Bingaman W, Becker AJ. Epilepsies associated with hippocampal sclerosis. Acta Neuropathol 2014;128(1):21-37. PMID 24823761
26: Cendes F, Theodore WH, Brinkmann BH, Sulc V, Cascino GD. Neuroimaging of epilepsy. Handb Clin Neurol 2016;136:985-1014. PMID 27430454
27: Chen B, Choi H, Hirsch LJ, et al. Cosmetic side effects of antiepileptic drugs in adults with epilepsy. Epilepsy Behav 2015;42:129-37. PMID 25513768
28: Cheval M, Houot M, Chastan N, et al. Early identification of seizure freedom with medical treatment in patients with mesial temporal lobe epilepsy and hippocampal sclerosis. J Neurol 2023;270(5):2715-23. PMID 36763175
29: Chung S, Ben-Menachem E, Sperling MR, et al. Examining the clinical utility of lacosamide: pooled analyses of three phase II/III clinical trials. CNS Drugs 2010;24(12):1041-54. PMID 21090838
30: Coan AC, Kobayashi E, Li LM, Cendes F. Quantification of hippocampal signal intensity in patients with mesial temporal lobe epilepsy. J Neuroimaging 2003;13(3):228-33. PMID 12889169
31: Coan AC, Kubota B, Bergo FP, Campos BM, Cendes F. 3T MRI quantification of hippocampal volume and signal in mesial temporal lobe epilepsy improves detection of hippocampal sclerosis. AJNR Am J Neuroradiol 2014;35(1):77-83. PMID 23868151
32: Costa AL, Yasuda CL, Franca MC Jr, Morita ME, Cendes F. Refractory epilepsy is highly associated with severe dentoalveolar and maxillofacial injuries. Epileptic Disord 2011;13(1):61-4. PMID 21393092
33: de Campos BM, Coan AC, Lin Yasuda C, Casseb RF, Cendes F. Large-scale brain networks are distinctly affected in right and left mesial temporal lobe epilepsy. Hum Brain Mapp 2016;37(9):3137-52. PMID 27133613
34: Deleo F, Garbelli R, Milesi G, et al. Short- and long-term surgical outcomes of temporal lobe epilepsy associated with hippocampal sclerosis: Relationships with neuropathology. Epilepsia 2015;57(2):306-15. PMID 26676889
35: de Souza JPSAS, Pimentel-Silva LR, Ayub G, et al. Transsylvian amygdalohippocampectomy for mesial temporal lobe epilepsy: Comparison of three different approaches. Epilepsia 2021;62(2):439-49. PMID 33449366
36: Diaz-Arrastia R, Agostini MA, Frol AB, et al. Neurophysiologic and neuroradiologic features of intractable epilepsy after traumatic brain injury in adults. Arch Neurol 2000;57(11):1611-6. PMID 11074793
37: Dorfer C, Rydenhag B, Baltuch G, et al. How technology is driving the landscape of epilepsy surgery. Epilepsia 2020;61(5):841-55. PMID 32227349
38: Engel J Jr, McDermott MP, Wiebe S, et al. Early surgical therapy for drug-resistant temporal lobe epilepsy: a randomized trial. JAMA 2012;307(9):922-30. PMID 22396514
39: Finke C, Pruss H, Heine J, et al. Evaluation of cognitive deficits and structural hippocampal damage in encephalitis with leucine-rich, glioma-inactivated 1 antibodies. JAMA Neurol 2017;74(1):50-9. PMID 27893017
40: Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017;58(4):522-30. PMID 28276060
41: Gambardella A, Gotman J, Cendes F, Andermann F. Focal intermittent delta activity in patients with mesiotemporal atrophy: a reliable marker of the epileptogenic focus. Epilepsia 1995;36(2):122-9. PMID 7821268
42: Gaspard N. Autoimmune epilepsy. Continuum (Minneap Minn) 2016;22(1 Epilepsy):227-45. PMID 26844739
43: Gleichgerrcht E, Munsell BC, Alhusaini S, et al. Artificial intelligence for classification of temporal lobe epilepsy with ROI-level MRI data: a worldwide ENIGMA-Epilepsy study. Neuroimage Clin 2021;31:102765. PMID 34339947
44: Goodkin O, Pemberton HG, Vos SB, et al. Clinical evaluation of automated quantitative MRI reports for assessment of hippocampal sclerosis. Eur Radiol 2021;31(1):34-44. PMID 32749588
45: Glauser T, Ben-Menachem E, Bourgeois B, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2013;54(3):551-63. PMID 23350722
46: Hammers A, Koepp MJ, Brooks DJ, Duncan JS. Periventricular white matter flumazenil binding and postoperative outcome in hippocampal sclerosis. Epilepsia 2005;46(6):944-8. PMID 15946336
47: Harden CL, Hopp J, Ting TY, et al. Practice parameter update: management issues for women with epilepsy--focus on pregnancy (an evidence-based review): obstetrical complications and change in seizure frequency: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology 2009;73(2):126-32. PMID 19398682
48: Hemb M, Palmini A, Paglioli E, et al. An 18-year follow-up of seizure outcome after surgery for temporal lobe epilepsy and hippocampal sclerosis. J Neurol Neurosurg Psychiatry 2013;84(7):800-5. PMID 23408065
49: Jama-António JMC, Yasuda CL, Cendes F. Neurocysticercosis and hippocampal atrophy: MRI findings and the evolution of viable or calcified cysts in patients with neurocysticercosis. Front Neurol 2019;10:449. PMID 31114540
50: Jehi L, Friedman D, Carlson C. The evolution of epilepsy surgery between 1991 and 2011 in nine major epilepsy centers across the United States, Germany, and Australia. Epilepsia 2015;56(10):1526-33. PMID 26250432
51: Jette N, Engel J. Refractory epilepsy is a life-threatening disease: lest we forget. Neurology 2016;86(21):1932-3. PMID 27164686
52: Jones-Gotman M, Smith ML. Neuropsychological profiles. Adv Neurol 2006;97:357-66. PMID 16383146
53: Kanner AM, Hesdorffer DC. Neuropsychiatric complications of epilepsy. Hand Clin Neurol 2012;107:461-82. PMID 22938989
54: Kobayashi E, Li LM, Lopes-Cendes I, Cendes F. Magnetic resonance imaging evidence of hippocampal sclerosis in asymptomatic, first-degree relatives of patients with familial mesial temporal lobe epilepsy. Arch Neurol 2002;59(12):1891-4. PMID 12470176
55: Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342(5):314-9. PMID 10660394
56: Labate A, Baggetta R, Trimboli M, et al. Insight into epileptic and physiological déjà vu: from a multicentric cohort study. Eur J Neurol 2019;26(3):407-14. PMID 30184312
57: Labate A, Gambardella A, Andermann E, et al. Benign mesial temporal lobe epilepsy. Nat Rev Neurol 2011;7(4):237-40. PMID 21263461
58: Laxer KD, Trinka E, Hirsch LJ, et al. The consequences of refractory epilepsy and its treatment. Epilepsy Behav 2014;37:59-70. PMID 24980390
59: Lee SB, Cho YJ, Jeon K, et al. Diagnosis of hippocampal sclerosis in children: comparison of automated brain MRI volumetry and readers of varying experience. AJR Am J Roentgenol 2021;217(1):223-34. PMID 32903057
60: Leong ECS, Seneviratne U. "Benign" temporal lobe epilepsy with hippocampal sclerosis: a forgotten entity? Epilepsy Behav Rep 2020;14:100407 PMID 33313502
61: Lewis DV, Voyvodic J, Shinnar S, et al. Hippocampal sclerosis and temporal lobe epilepsy following febrile status epilepticus: The FEBSTAT study. Epilepsia 2024;65(6):1568-80. PMID 38606600
62: Leypoldt F, Wandinger KP, Bien CG, Dalmau J. Autoimmune encephalitis. Eur Neurol Rev 2013;8(1):31-7. PMID 27330568
63: Li LM, Cendes F, Andermann F, et al. Surgical outcome in patients with epilepsy and dual pathology. Brain 1999;122 (Pt 5):799-805. PMID 10355666
64: Lopez SM, Aksman LM, Oxtoby NP, et al. Event-based modeling in temporal lobe epilepsy demonstrates progressive atrophy from cross-sectional data. Epilepsia 2022;63(8):2081-95. PMID 35656586
65: Louis S, Morita-Sherman M, Jones S, et al. Hippocampal sclerosis detection with NeuroQuant compared with neuroradiologists. AJNR Am J Neuroradiol 2020;41(4):591-7. PMID 32217554
66: Mathern GW, Adelson PD, Cahan LD, Leite JP. Hippocampal neuron damage in human epilepsy: Meyer's hypothesis revisited. Prog Brain Res 2002;135:237-51. PMID 12143344
67: Mathern GW, Babb TL, Vickrey BG, Melendez M, Pretorius JK. The clinical-pathogenic mechanisms of hippocampal neuron loss and surgical outcomes in temporal lobe epilepsy. Brain 1995;118 (Pt 1):105-18. PMID 7894997
68: Mathern GW, Bertram EH. Recurrent limbic seizures do not cause hippocampal neuronal loss: a prolonged laboratory study. Neurobiol Dis 2021;148:105183. PMID 33207277
69: McClelland AC, Gomes WA, Shinnar S, et al. Quantitative evaluation of medial temporal lobe morphology in children with febrile status epilepticus: results of the FEBSTAT study. AJNR Am J Neuroradiol 2016;37(12):2356-62. PMID 27633809
70: Mintzer S, Cendes F, Soss J, et al. Unilateral hippocampal sclerosis with contralateral temporal scalp ictal onset. Epilepsia 2004;45(7):792-802. PMID 15230704
71: Montenegro MA, Ferreira CM, Cendes F, Li LM, Guerreiro CA. Clobazam as add-on therapy for temporal lobe epilepsy and hippocampal sclerosis. Can J Neurol Sci 2005;32(1):93-6. PMID 15825553
72: Morita ME, Yasuda CL, Betting LE, et al. MRI and EEG as long-term seizure outcome predictors in familial mesial temporal lobe epilepsy. Neurology 2012;79(24):2349-54. PMID 23197748
73: Mulder ER, de Jong RA, Knol DL, et al. Hippocampal volume change measurement: quantitative assessment of the reproducibility of expert manual outlining and the automated methods FreeSurfer and FIRST. Neuroimage 2014;92:169-81. PMID 24521851
74: Nogueira MH, Yasuda CL, Coan AC, Kanner AM, Cendes F. Concurrent mood and anxiety disorders are associated with pharmacoresistant seizures in patients with MTLE. Epilepsia 2017;58(7):1268-76. PMID 28555776
75: Patterson KP, Baram TZ, Shinnar S. Origins of temporal lobe epilepsy: febrile seizures and febrile status epilepticus. Neurotherapeutics 2014;11(2):242-50. PMID 24604424
76: Perucca E, Brodie MJ, Kwan P, Tomson T. 30 years of second-generation antiseizure medications: impact and future perspectives. Lancet Neurol 2020;19(6):544-56. PMID 32109411
77: Pimentel-Silva LR, Casseb RF, Cordeiro MM, et al. Interactions between in vivo neuronal-glial markers, side of hippocampal sclerosis, and pharmacoresponse in temporal lobe epilepsy. Epilepsia 2020;61(5):1008-18. PMID 32347553
78: Popkirov S, Ismail FS, Grönheit W, Kapauer M, Wellmer J, Bien CG. Progressive hippocampal sclerosis after viral encephalitis: potential role of NMDA receptor antibodies. Seizure 2017;51:6-8. PMID 28750305
79: Salgado PC, Yasuda CL, Cendes F. Neuroimaging changes in mesial temporal lobe epilepsy are magnified in the presence of depression. Epilepsy Behav 2010;19(3):422-7. PMID 20850388
80: Sanchez SS, Bustos JA, Del Brutto OH, et al. Hippocampal atrophy/sclerosis is associated with old, calcified parenchymal brain neurocysticercosis, but not with more recent, viable infections. Am J Trop Med Hyg 2021;106(1):215-8. PMID 34695784
81: Secchi TL, Brondani R, Bragatti JA, Bizzi JWJ, Bianchin MM. Evaluating the association of calcified neurocysticercosis and mesial temporal lobe epilepsy with hippocampal sclerosis in a large cohort of patients with epilepsy. Front Neurol 2022;12:769356. PMID 35153977
82: Semah F, Picot MC, Adam C, et al. Is the underlying cause of epilepsy a major prognostic factor for recurrence? Neurology 1998;51(5):1256-62. PMID 9818842
83: Singh G, Sander JW. Neurocysticercosis as a probable risk factor for hippocampal sclerosis. Arq Neuropsiquiatr 2018;76(11):783-90. PMID 30570023
84: Stephen LJ, Brodie MJ. Antiepileptic drug monotherapy versus polytherapy: pursuing seizure freedom and tolerability in adults. Curr Opin Neurol 2012;25(2):164-72. PMID 22322411
85: Tai XY, Bernhardt B, Thom M, et al. Review: neurodegenerative processes in temporal lobe epilepsy with hippocampal sclerosis: clinical, pathological and neuroimaging evidence. Neuropathol Appl Neurobiol 2018;44(1):70-90. PMID 29288503
86: Thom M. Hippocampal sclerosis: progress since Sommer. Brain Pathol 2009;19(4):565-72. PMID 18761661
87: Vakharia VN, Duncan JS, Witt JA, Elger CE, Staba R, Engel J Jr. Getting the best outcomes from epilepsy surgery. Ann Neurol 2018;83(4):676-90. PMID 29534299
88: van Gassen KL, De WM, Koerkamp MJ, et al. Possible role of the innate immunity in temporal lobe epilepsy. Epilepsia 2008;49(6):1055-65. PMID 18076643
89: van Sonderen A, Thijs RD, Coenders EC, et al. Anti-LGI1 encephalitis: clinical syndrome and long-term follow-up. Neurology 2016;87(14):1449-56. PMID 27590293
90: Velasco TR, Wichert-Ana L, Leite JP, et al. Accuracy of ictal SPECT in mesial temporal lobe epilepsy with bilateral interictal spikes. Neurology 2002;59(2):266-71. PMID 12136068
91: Wiebe S, Blume WT, Girvin JP, Eliasziw M; Effectiveness and Efficiency of Surgery for Temporal Lobe Epilepsy Study Group. A randomized, controlled trial of surgery for temporal-lobe epilepsy. N Engl J Med 2001;345(5):311-8. PMID 11484687
92: Wlodarczyk BJ, Palacios AM, George TM, Finnell RH. Antiepileptic drugs and pregnancy outcomes. Am J Med Genet A 2012;158A(8):2071-90. PMID 22711424
93: Yasuda CL, Cendes F. Neuroimaging for the prediction of response to medical and surgical treatment in epilepsy. Expert Opin Med Diagn 2012;6(4):295-308. PMID 23480740
94: Yasuda CL, Centeno M, Vollmar C, et al. The effect of topiramate on cognitive fMRI. Epilepsy Res 2013;105(1-2):250-5. PMID 23333471
95: Yasuda CL, Chen Z, Beltramini GC, et al. Aberrant topological patterns of brain structural network in temporal lobe epilepsy. Epilepsia 2015;56(12):1992-2002. PMID 26530395
96: Zaccara G, Perucca E. Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs. Epileptic Disord 2014;16(4):409-31. PMID 25515681
97: Zanao TA, Lopes TM, de Campos BM, Yasuda CL, Cendes F. Patterns of default mode network in temporal lobe epilepsy with and without hippocampal sclerosis. Epilepsy Behav 2021;121(Pt B):106523. PMID 31645315

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Fernando Cendes MD PhD

Dr. Cendes of the University of Campinas - UNICAMP has no relevant financial relationships to disclose.
See Profile

Editor

Jerome Engel Jr MD PhD

Dr. Engel of the David Geffen School of Medicine at the University of California, Los Angeles, has no relevant financial relationships to disclose.
See Profile

Former Authors

Clarissa Lin Yasuda MD PhD

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Hippocampal atrophy in epilepsy

Associated Disorders

Dual pathology
Familial temporal lobe epilepsy
Focal cortical dysplasia type IIIa

Also Relevant

Familial mesial temporal lobe epilepsy
Febrile seizures
Hippocampal and parahippocampal seizures
Mesial temporal lobe epilepsy with hippocampal sclerosis
Pharmacological treatment of epilepsy in adolescents and adults

Clinical Categories

Epilepsy & Seizures

	• Other familial temporal lobe epilepsies
	• Mesial temporal lobe epilepsy with hippocampal sclerosis
	• Malformations of cortical development
	• Low-grade tumors in the mesial temporal region (12)

Hippocampal atrophy in epilepsy …

Hippocampal atrophy in epilepsy

Introduction

Overview

Key points

Historical note and nomenclature

Clinical manifestations

Presentation and course

Pathophysiology

Differential diagnosis

Diagnostic workup

Syndromes and diseases in which the seizure type occurs

Adolescent to adult

Prognosis and complications

Management

Media

References

Contributors

Author

Editor

Former Authors

Patient Profile

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Photosensitive occipital lobe epilepsy

Intermittent explosive disorder

Pyridoxine/P5P-dependent developmental epileptic encephalopathy

Reflex seizures

Anti-LGI1 encephalitis

Self-limited (familial) neonatal epilepsy

Epilepsy with auditory features

Alcohol withdrawal seizures

Hippocampal atrophy in epilepsy

Introduction

Overview

Key points

Historical note and nomenclature

Clinical manifestations

Presentation and course

Pathophysiology

Differential diagnosis

Diagnostic workup

Syndromes and diseases in which the seizure type occurs

Adolescent to adult

Prognosis and complications

Management

Media

References

Contributors

Author

Editor

Former Authors

Patient Profile

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Photosensitive occipital lobe epilepsy

Intermittent explosive disorder

Pyridoxine/P5P-dependent developmental epileptic encephalopathy

Reflex seizures

Anti-LGI1 encephalitis

Self-limited (familial) neonatal epilepsy

Epilepsy with auditory features

Alcohol withdrawal seizures

This is an article preview.
Start a Free Account
to access the full version.